Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ranolazine (Primary)
- Indications Myocardial reperfusion injury
- Focus Therapeutic Use
- 23 Feb 2021 Status changed from not yet recruiting to withdrawn prior to enrolment due to inability to produce placebo tablets similar to the drug tested.
- 12 Apr 2019 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
- 12 Apr 2019 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2020.